You just read:

Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio for Treatment of Multidrug-Resistant, Gram-Negative Infections

News provided by

Spero Therapeutics

Jan 31, 2017, 08:30 ET